Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casdatifan + cabozantinib versus placebo + cabozantinib in advanced clear cell renal cell carcinoma
2024-515023-11-00Phase 3Authorised
- Sponsor
- Arcus Biosciences
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in clear cell renal cell carcinoma (ccRCC) comparing Casdatifan + cabozantinib with Placebo + cabozantinib (2 arms). Primary endpoint: Progression-free survival. Planned start Jan 2026; status: authorised.
02
Drugs
casdatifancabozantinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2024-515023-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515023-11-00.